- Clone:
- REA1019 | 14B11
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC Glossary
- Select a conjugate:
- Select a size:
Related products for Ly-49C/F/I/H Antibody, anti-mouse, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated Ly-49C/F/I/H (REA1019) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for Ly-49C/F/I/H. Splenocytes from C57BL/6 mice were stained with Ly-49C/F/I/H antibodies followed by a suitable counterstain as a control matching REA isotype control antibody was used. Flow cytometry analysis was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. The recommended titers of respective antibodies from different suppliers were used.
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using Ly-49C/F/I/H (REA1019). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REA1019 recognizes a common epitope of the mouse Ly-49C/F/I/H family members which are single-pass type II C-type lectin-like membrane glycoproteins also known as Ly-49 inhibitory receptors C, F, and I and activating receptor H. It does not react with other Ly-49 members. The Ly-49 receptors are encoded by a family of highly polymorphic and polygenic genes within the mouse NK gene complex which includes genes that encode both inhibitory and activating Ly-49 receptors. Ly-49 receptors recognize MHC-I and MHC-I–like proteins on normal as well as altered cells. They are described as being expressed on both the developing and mature NK cells. The inhibitory Ly-49 receptors are involved in NK cell education, a process in which NK cells acquire function and tolerance toward cells that express “self-MHC-I.” On the other hand, the activating Ly-49 receptors recognize altered cells expressing activating ligands. Ly-49 receptors have been described on multiple NK cell subsets, such as uterine NK and memory NK cells, as well as NKT cells, dendritic cells, plasmacytoid dendritic cells, macrophages, neutrophils, and cells of the adaptive immune system such as activated T cells and regulatory CD8+ T cells.
Additional information: Clone REA1019 displays negligible binding to Fc receptors.
Klra3, Klra6, Klra8, Klra9
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Rahim, M. M. et al. (2014) Ly49 receptors: innate and adaptive immune paradigms. Front Immunol 5: 145-145
- Tu, M. M. et al. (2014) Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells. Cancer Res. 74 (14): 3684-3694
- Wong, S. et al. (1991) Ly-49 multigene family. New members of a superfamily of type II membrane proteins with lectin-like domains. J Immunol 147 (4): 1417-1423